A study from researchers at the University of Michigan and the University of California San Diego has shed light on a previously poorly understood aspect of breast cancer recurrence: how cancer cells ...
Puma Biotechnology announced the grant of an inducement award to a November new hire, as required under Nasdaq Listing Rule ...
APL researchers used artificial intelligence and two APL-patented imaging technologies to improve the accuracy and efficiency ...
When Julie Durbin was undergoing cancer treatment, she was always cold. She would bring a cardigan, a sweater that opens in ...
Hosted on MSN7h
Merck's ADC Drug Gets FDA Breakthrough Therapy Tag in NSCLCMerck MRK announced that the FDA has granted breakthrough therapy designation (BTD) to sacituzumab tirumotecan (sac-TMT) for ...
Today, women with estrogen-sensitive breast cancer receive anti-hormonal therapy. Researchers now show that postmenopausal ...
A study from researchers at the University of Michigan and the University of California San Diego has shed light on a ...
Stay up to date on the latest AI technology advancements and learn about the challenges and opportunities AI presents now and ...
Researchers at Baylor College of Medicine and Rice University have received a $2.3 million Breakthrough Award from the ...
Linda D’Addario, a cancer survivor, now mentors others through Cancer Hope Network, a program now available at five area ...
Schad, a compassionate soul and dedicated community member, passed away on Friday, November 29, 2024, at the age of 50 at CHP ...
GlobalData on MSN1d
Novartis and Olema expand alliance with $250m to boost breast cancer trialsOlema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback